Altimmune price target lowered to $20 from $25 at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on Altimmune (ALT) to $20 from $25 and keeps a Buy rating on the shares. The price target cut reflects share-count dilution from the January and April offerings, notes the analyst, who sees the offerings removing a financing overhang and views a fully funded MASH program through the 2029 PERFORMA 52-week topline readout as “a clear net positive.”